Professor of Medicine
UC Davis Comprehensive Cancer Center
David R. Gandara, MD, has no real or apparent conflicts of interest to report.
Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Heather Wakelee, MD, has disclosed that she has received consulting fees from ACEA, Genentech, Helsinn, Peregrine, and Pfizer; and funds for research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Clovis, Exelixis, Genentech/Roche, Gilead, Lilly, Novartis, Pfizer, Pharmacyclics, and Xcovery.
David R. Gandara, MD, and I are looking forward to several interesting studies on lung cancer that are being reported at this year’s ASCO annual meeting with the potential to affect practice. In particular, the first phase III trial data comparing alectinib, a second-generation ALK inhibitor, with crizotinib as first-line or second-line therapy for patients with ALK-positive metastatic NSCLC will be reported. These results will begin to inform our decisions on how to best use ALK inhibitors for these patients. A second key study will report OS data from an early-phase trial for the first targeted therapy for SCLC. Rovalpituzumab tesirine (Rova-T) is an antibody–drug conjugate that targets delta-like protein 3 (DLL3) that is expressed in approximately 80% of SCLC tumors but not normal tissue. Previous data suggested significant antitumor activity in previously treated patients with SCLC and high levels of DLL3 expression.
In addition to these 2 key studies, we will keep an eye on other important studies with the potential to affect our practices now or in the near future including:
Follow our coverage of these and other important studies in lung cancer presented at ASCO 2016 with some of these studies available as downloadable summary slidesets as well as our analysis included in an online activity.
What are you most looking forward to seeing at ASCO 2016? Please share your thoughts in the comment box below.